Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.
Mollee P, Reynolds J, Janowski W, Quach H, Campbell P, Gibbs S, Lee S, Lee E, Taylor K, Cochrane T, Wallington-Gates C, Kwok F, Weber N, Kerridge I, Weston H, Ho PJ, Leahy MF, Horvath N, Spencer A. Mollee P, et al. Blood Adv. 2024 Jul 23;8(14):3721-3730. doi: 10.1182/bloodadvances.2023012539. Blood Adv. 2024. PMID: 38739707 Free PMC article. Clinical Trial.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Palumbo A, et al. N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. N Engl J Med. 2012. PMID: 22571200 Free article. Clinical Trial.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Benboubker L, et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. N Engl J Med. 2014. PMID: 25184863 Free article. Clinical Trial.
A Comparison of Peripherally Inserted Central Catheter Materials.
Ullman AJ, August D, Kleidon TM, Walker RM, Marsh N, Bulmer AC, Pearch B, Runnegar N, Leema J, Lee-Archer P, Biles C, Gibson V, Royle R, Southam K, Byrnes J, Chopra V, Coulthard A, Mollee P, Rickard CM, Harris PNA, Ware RS. Ullman AJ, et al. Among authors: mollee p. N Engl J Med. 2025 Jan 9;392(2):161-172. doi: 10.1056/NEJMoa2406815. N Engl J Med. 2025. PMID: 39778170 Clinical Trial.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Coiffier B, et al. Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1. Lancet Oncol. 2011. PMID: 21724462 Clinical Trial.
Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.
Lim KJC, Wellard C, Moore E, Ninkovic S, Chng WJ, Spencer A, Mollee P, Hocking J, Ho PJ, Janowski W, Kim K, McCaughan G, Dun K, McQuilten ZK, Chen F, Quach H. Lim KJC, et al. Among authors: mollee p. Clin Lymphoma Myeloma Leuk. 2024 Nov 9:S2152-2650(24)02402-9. doi: 10.1016/j.clml.2024.11.002. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39616008 No abstract available.
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.
Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Huynh K, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, Spencer A, McQuilten ZK. Irving A, et al. Among authors: mollee p. PLoS One. 2024 Aug 27;19(8):e0308812. doi: 10.1371/journal.pone.0308812. eCollection 2024. PLoS One. 2024. PMID: 39190684 Free PMC article.
Variation in immunoglobulin use and impact on survival in myeloma.
Chai KL, Wellard C, Thao L, Aoki N, Moore EM, Augustson BM, Bapat A, Blacklock H, Chng WJ, Cooke R, Forsyth CJ, Goh YT, Hamad N, Harrison SJ, Ho PJ, Hocking J, Kerridge I, Kim JS, Kim K, King T, McCaughan GJ, Mollee P, Morrissey CO, Murphy N, Quach H, Tan XN, Tso AC, Wong KS, Yoon SS, Spencer A, Wood EM, McQuilten ZK. Chai KL, et al. Among authors: mollee p. EJHaem. 2024 Jun 16;5(4):690-697. doi: 10.1002/jha2.938. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157592 Free PMC article.
184 results